OLUFEMI OGUNDEJI: Open Payments
NPI 1912226697 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,760 in 83 payments from 13 companies in 2025. Trend: 2023 $1,692 · 2024 $1,062 · 2025 $1,760
Food & beverage: $1,752Education: $8
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $353 |
| Alkermes, Inc. | 8 | $234 |
| ABBVIE INC. | 12 | $228 |
| Janssen Pharmaceuticals, Inc | 10 | $187 |
| Teva Pharmaceuticals USA, Inc. | 5 | $132 |
| Lundbeck LLC | 6 | $126 |
| E.R. Squibb & Sons, L.L.C. | 6 | $120 |
| Otsuka America Pharmaceutical, Inc. | 6 | $120 |
| Braeburn Inc. | 5 | $93 |
| LivaNova USA, Inc. | 2 | $76 |
Products named: INGREZZA, VRAYLAR, INVEGA SUSTENNA, REXULTI, LYBALVI, COBENFY, ARISTADA, BRIXADI.
Industry payments across LA — which companies pay providers there.
